Shared on15 Aug 25
Analysts maintain a cautious stance on Quanterix due to near-term uncertainty, weak Q2 results, and biopharma sector headwinds, keeping the price target unchanged at $6.00. Analyst Commentary Downgrade reflects a lack of near-term visibility and absence of clear catalysts to drive the stock higher.
Shared on24 Apr 25Fair value Decreased 5.45%
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on17 Apr 25Fair value Decreased 4.30%
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on09 Apr 25
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on02 Apr 25Fair value Increased 26%
AnalystConsensusTarget has increased revenue growth from 8.3% to 11.3%, increased future PE multiple from 23.2x to 29.0x and increased shares outstanding growth rate from 0.0% to 0.0%.